Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AVITA Medical (RCEL) EBIT (2018 - 2025)

AVITA Medical filings provide 8 years of EBIT readings, the most recent being -$10.4 million for Q4 2025.

  • On a quarterly basis, EBIT fell 130.92% to -$10.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$42.5 million, a 227.81% decrease, with the full-year FY2025 number at -$42.5 million, down 227.79% from a year prior.
  • EBIT hit -$10.4 million in Q4 2025 for AVITA Medical, down from -$9.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $33.7 million in Q4 2024 to a low of -$17.2 million in Q1 2024.
  • Median EBIT over the past 5 years was -$9.7 million (2022), compared with a mean of -$6.3 million.
  • Biggest five-year swings in EBIT: tumbled 176.68% in 2023 and later soared 374.26% in 2024.
  • AVITA Medical's EBIT stood at -$5.9 million in 2021, then surged by 369.04% to $16.0 million in 2022, then tumbled by 176.68% to -$12.3 million in 2023, then soared by 374.26% to $33.7 million in 2024, then tumbled by 130.92% to -$10.4 million in 2025.
  • The last three reported values for EBIT were -$10.4 million (Q4 2025), -$9.2 million (Q3 2025), and -$11.1 million (Q2 2025) per Business Quant data.